GLP-1 Agonists Approved for Weight Loss

Last reviewed: May 24, 2026

Last updated: May 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Four GLP-1 receptor agonists are FDA-approved for chronic weight management: semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), liraglutide (Saxenda), and dulaglutide (Trulicity). Tirzepatide demonstrated the highest mean weight loss at 21.4% of baseline body weight over 72 weeks in SURMOUNT trials.

Weight loss medication selection is not one-size-fits-all. Patient genetics, baseline metabolic markers, comorbidities, and GLP-1 receptor pathway variations influence how individuals may respond. PlexusDx supports precision conversations between patients and providers by contextualizing approved options with personalized biomarker and genetic data.

FDA-Approved GLP-1 Agonists: Approval Timeline and Mechanism

Semaglutide (Wegovy) received FDA approval for chronic weight management in 2021, followed by tirzepatide (Zepbound) in 2023. Both work by stimulating GLP-1 receptors in the hypothalamus to increase satiety and reduce hunger signals. Liraglutide (Saxenda) and dulaglutide (Trulicity) were approved earlier but with more modest efficacy.

Each medication binds to GLP-1 receptors with slightly different affinities and tissue distribution patterns. Tirzepatide, a dual GIP/GLP-1 agonist, activates both GLP-1 and glucose-dependent insulinotropic peptide (GIP) pathways, which may explain its superior weight loss outcomes in clinical trials.

Comparative Clinical Efficacy and Trial Outcomes

Randomized controlled trials provide objective benchmarks for each approved agent. Mean weight loss varies significantly by medication, baseline BMI, and treatment duration. Below is a summary of pivotal trial data across approved GLP-1 agents for weight loss.

Medication	Trial Name	Duration	Mean Weight Loss	Key Population
Tirzepatide (Zepbound)	SURMOUNT-4	72 weeks	21.4% of baseline	BMI ≥27 with ≥1 comorbidity
Semaglutide (Wegovy)	STEP-4	68 weeks	17.4% of baseline	BMI ≥30 or ≥27 with comorbidity
Liraglutide (Saxenda)	SCALE	56 weeks	8.4% of baseline	BMI ≥30 or ≥27 with comorbidity
Dulaglutide (Trulicity)	REWIND	104 weeks	2.5 kg (post-hoc)	Type 2 diabetes, secondary indication

Patient Selection and Metabolic Biomarker Context

FDA approval requires BMI ≥ 30 kg/m² or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, obstructive sleep apnea). Baseline fasting glucose, insulin resistance markers, and lipid profiles may provide additional context for medication selection and expected metabolic benefits.

Patients with impaired fasting glucose or prediabetes may experience differential glucose-lowering effects depending on GLP-1 pathway activation patterns. Genetic variants in GIPR, and FTO genes may influence baseline metabolic state and individual response trajectories, though clinical response prediction remains complex.

Safety Considerations and Provider-Led Personalization

Common adverse effects include nausea, vomiting, diarrhea, and constipation; serious risks include acute pancreatitis, thyroid concerns, and gallbladder complications. Contraindications include personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2. A qualified healthcare provider must assess individual safety profiles.

Compounded formulations sourced from licensed 503A pharmacies offer dosing flexibility and cost accessibility compared to branded options. Starting with lower doses allows for gradual titration and improved tolerability. Genetic predisposition testing may help contextualize individual metabolic baseline and support a more informed conversation with your provider about which approved agent aligns with your health profile.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test may help provide context regarding your genetic predispositions in peptide and metabolic pathways. Key variants in GIPR (rs1800437) influence receptor expression and signaling efficiency. These predispositions should be interpreted with a qualified healthcare provider as part of a comprehensive clinical assessment.

The genetic test reveals how your inherited variants may influence baseline metabolic state and GLP-1 pathway function. However, genetics alone do not predict exact medication response; environmental factors, diet, exercise, comorbidities, and medication interactions significantly influence real-world outcomes. Genetic data can support a more personalized conversation, not replace medical evaluation.

Understanding your genetic predispositions in GLP-1 and GIP receptor pathways, combined with biomarker assessment and clinical history, can help your healthcare provider select the FDA-approved GLP-1 agent most likely to align with your unique metabolic profile and treatment goals.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

When did Wegovy and Zepbound receive their weight-management approvals?

The article says semaglutide as Wegovy was approved for chronic weight management in 2021, and tirzepatide as Zepbound followed in 2023. It describes both as working by stimulating GLP-1 receptors in the hypothalamus to increase satiety and reduce hunger signals. Liraglutide, sold as Saxenda, was approved earlier, which the article pairs with more modest efficacy in its comparison of the agents.

Why does tirzepatide outperform GLP-1-only agents in the trials cited here?

Because of its second receptor target, in the article's explanation. It describes tirzepatide as a dual agonist activating both GLP-1 and glucose-dependent insulinotropic peptide pathways, which it says may account for the superior weight loss seen in trials. It also notes each agent binds GLP-1 receptors with slightly different affinities and tissue distribution patterns, so the class is not interchangeable.

What weight loss did liraglutide produce in the SCALE trial cited here?

The article reports a mean loss of 8.4 percent of baseline body weight over 56 weeks in SCALE, in a population with a BMI of 30 or above, or 27 or above with a comorbidity. It contrasts this with larger figures reported for newer agents over longer trial durations. The article uses these benchmarks to show mean weight loss varies substantially by medication and by how long a trial ran.

What BMI criteria does the article attach to these approvals?

A BMI of 30 kg/m2 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, type 2 diabetes or obstructive sleep apnea. The article adds that baseline fasting glucose, insulin resistance markers and lipid profiles give further context for the metabolic benefits someone might see. Those criteria are applied by a prescriber rather than self-assessed.

What serious risks does the article name beyond the common digestive effects?

Acute pancreatitis, thyroid concerns, and gallbladder complications, which the article separates from the common adverse effects of nausea, vomiting, diarrhea and constipation. It names personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 as contraindications. The article says a qualified healthcare provider must assess individual safety profiles before any of these agents is prescribed.

Related Reading

• Glp 1 Receptor Agonists For Weight Loss
• Glp 1 For Weight Loss 2
• Glp 1 Weight Loss Before And After
• Glp 1 Dosage For Weight Loss

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.